Meissa Vaccines, Inc.   Report issue

For profit Phase 1 Phase 2
Founded: San Francisco CA United States (2014)

Organization Overview

First Clinical Trial
2020
NCT04227210
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Meissa Vaccines, Inc.

Active Ingredients

Drugs in Phase 2 Trials (1)

mv-012-968 (4 trials)

Drugs in Phase 1 Trials (1)

mv-014-212 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Infections (Phase 2)

Respiratory Syncytial Virus Infections (Phase 2)

Virus Diseases (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 5
  • # of Trial APIs: 2